Canarypox and fowlpox viruses as recombinant vaccine vectors: a biological and immunological comparison

Antiviral Research
Carlo ZanottoAntonia Radaelli

Abstract

Canarypox and fowlpox viruses represent alternative vaccine vectors due to their natural host-range restriction to avian species. Although they cannot replicate in mammals, they correctly express transgenes in human cells and elicit a complete immune response in vaccinated subjects. Several studies have evaluated their genomic differences and protective efficacy in preclinical trials, but detailed information is not available for their transgene expression, cytokine modulation and abortive replication in mammals. This study demonstrates that the heterologous HIV gag/pol and env genes are more efficiently expressed by fowlpox in non-immune and immune cells. The production of retrovirus-like particles, the longer transgene expression, and a balanced cytokine induction may confer to fowlpox-based recombinants the ability to elicit a better immune response.

References

Mar 1, 1991·Vaccine·J TaylorE Paoletti
Dec 1, 1988·Vaccine·J Taylor, E Paoletti
Sep 1, 1994·Vaccine·A Radaelli, C De Giuli Morghen
Nov 15, 1997·Journal of the National Cancer Institute·K R IrvineN P Restifo
Feb 15, 2001·The Journal of Infectious Diseases·UNKNOWN AIDS Vaccine Evaluation Group 022 Protocol Team
Apr 11, 2001·The Journal of Infectious Diseases·R B BelsheUNKNOWN National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group and HIV Network for Prevention Trials (H
May 30, 2002·Virology·C L AfonsoD L Rock
Dec 18, 2002·The Journal of Biological Chemistry·Florian PuehlerPeter Staeheli
Aug 26, 2003·The Veterinary Record·H PouletP Desmettre
Dec 13, 2003·Journal of Virology·E R TulmanD L Rock
Jan 27, 2004·Vaccine·Guy de BruynMichael C Keefer
Mar 11, 2005·Expert Review of Vaccines·Michael A SkinnerMatthew G Cottingham
Jul 20, 2005·The Journal of Infectious Diseases·Sabine Kinloch-de LoesUNKNOWN QUEST Study Group
Sep 2, 2005·The Journal of Infectious Diseases·Paul A GoepfertUNKNOWN NIAID HIV Vaccine Trials Network
Oct 22, 2009·The New England Journal of Medicine·Supachai Rerks-NgarmUNKNOWN MOPH-TAVEG Investigators

❮ Previous
Next ❯

Citations

Apr 13, 2013·Journal of Translational Medicine·Sole Maria PacchioniAntonia Radaelli
Apr 9, 2015·Viruses·Lucas Sánchez-SampedroMariano Esteban
Aug 22, 2012·Human Vaccines & Immunotherapeutics·Carmen Elena GómezMariano Esteban
Dec 16, 2017·MSphere·Quazim A AlayoPablo Penaloza-MacMaster

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.